Jupiter Neurosciences, Inc. JUNS
Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a CNS/neurology/psychiatry drug developer. Its lead program, JOTROL (enhanced oral resveratrol formulation), is in Phase 2 for Parkinson's disease. Its next catalyst on record is JOTROL: Phase IIa Parkinson's disease results (Q2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: JOTROL — Phase IIa Parkinson's disease results (Q2 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| JOTROL | Parkinson's disease (Phase IIa) | small molecule | Phase 2 |
| JOTROL | mild cognitive impairment and Alzheimer's disease (planned after the Parkinson's study) | small molecule | Pre-clinical |
| ALA-002 (next-generation MDMA formulation, US license from PharmAla, July 2026) | — | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.